DERM · Journey Medical Corp
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $68.18M | $61.86M | $56.13M | $79.18M | $73.67M | $63.13M | $44.53M | |
| — | $20.92M | $20.88M | $22.89M | $30.78M | $32.08M | $14.59M | |
| — | $40.93M | $35.26M | $56.29M | $42.89M | $31.05M | $29.94M | |
| — | 66.17% | 62.81% | 71.09% | 58.23% | 49.18% | 67.23% | |
| — | $480K | $9.86M | $7.54M | $10.94M | $2.74M | — | |
| $42.91M | $44.37M | $40.2M | $43.91M | $59.47M | $39.83M | $22.09M | |
| $4.22M | $4.26M | $3.42M | $3.77M | $4.28M | $2.47M | $1.42M | |
| — | — | — | — | — | $0 | $5000 | |
| $71.19M | $70.03M | $69.81M | $81.25M | $101.19M | $98.02M | $36.68M | |
| -$3.01M | -$8.17M | -$13.68M | -$2.07M | -$27.52M | -$34.88M | $7.85M | |
| — | -13.21% | -24.36% | -2.62% | -37.35% | -55.25% | 17.63% | |
| — | — | — | — | — | -$34.88M | $7.86M | |
| $3.67M | $3.7M | $2.7M | $1.7M | $2.02M | $7.03M | $698K | |
| -$3.08M | -$3.2M | -$934K | -$1.56M | -$2.05M | -$7.48M | -$698K | |
| -$6.09M | -$11.37M | -$14.61M | -$3.63M | -$29.57M | -$42.36M | $7.15M | |
| — | $60K | $61K | $221K | $63K | $1.63M | $1.87M | |
| -$6.1M | -$11.43M | -$14.67M | -$3.85M | -$29.63M | -$43.99M | $5.28M | |
| — | -18.48% | -26.14% | -4.87% | -40.22% | -69.68% | 11.86% | |
| USD/shares | -$0.22 | -$0.47 | -$0.72 | -$0.21 | -$1.69 | -$4.32 | $0.58 |
| USD/shares | -$0.22 | -$0.47 | -$0.72 | -$0.21 | -$1.69 | -$4.32 | $0.49 |
| shares | — | 24.5M | 20.43M | 18.23M | 17.53M | 10.19M | 9.14M |
| shares | — | 24.5M | 20.43M | 18.23M | 17.53M | 10.19M | 10.84M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 51 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
EV/Adj. EBITDA uses the company-stated “Non-GAAP Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses the company-stated “Non-GAAP Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Dermatological Segment | $61,858,000 | $56,134,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Qbrexza | $25,014,000 | $25,114,000 | $25,410,000 | — | — |
| Emrosi | $14,745,000 | — | — | — | — |
| Accutane | $12,882,000 | $19,407,000 | $20,168,000 | $10,053,000 | — |
| Foam Franchise Products Amzeeq Zilxi | $5,859,000 | $6,652,000 | — | — | — |
| Other Legacy | $2,739,000 | $3,961,000 | $5,921,000 | — | — |
| Amzeeq | — | — | $6,201,000 | — | — |
| Exelderm | — | — | — | $5,363,000 | $4,453,000 |
| Other Branded Products | — | — | — | $37,000 | -$148,000 |
| Qbrexa | — | — | — | $17,056,000 | — |
| Targadox | — | — | — | $22,378,000 | $30,708,000 |
| Ximino | — | — | — | $8,247,000 | $9,518,000 |
| Zilxi | — | — | $1,962,000 | — | — |